SCHEMBL408276

SCHEMBL408276

CCCSC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.50
RECQL P46063 1/20 0.48
EPHX1 P07099 1/20 0.48
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR119 Q8TDV5 4/20 0.45
KDM4E B2RXH2 2/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
DPP4 P27487 1/20 0.43
PKM P14618 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25699536 0.91 HPGD (0.44) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL4552184 0.90 HPGD (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL2770843 0.87 HPGD (0.53) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL27633297 0.84 HPGD (0.53) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL20802890 0.83 HPGD (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL1100009 0.82 HPGD (0.46) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL6132369 0.81 HPGD (0.45) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL14836460 0.81 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL9174450 0.81 HPGD (0.50) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL6132776 0.80 GPR119 (0.44) HPGDRECQLEPHX1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
WO-2008011130-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed
WO-2008011130-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065196-A1 AMIDE COMPOUNDS DGAT2, DGAT1, DLAT HPGD 1034/4885RECQL 3885/4885EPHX1 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.